Alice S. Mims

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute — United States

Medicine · Health Sciences

37h-index6.6kcitations445works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(285), Chronic Myeloid Leukemia Treatments(114), Myeloproliferative Neoplasms: Diagnosis and Treatment(61), Histone Deacetylase Inhibitors Research(61), Chronic Lymphocytic Leukemia Research(58)

Publications445 total

Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Supplementary Data from Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2025Open Access
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma
2025Open Access
Real‐world analysis of <scp>CPX</scp> ‐351 in <scp>AML</scp> ‐ <scp>MR</scp> : A multicentre study from the <scp>MARROW</scp> consortium
British Journal of Haematology·2025Open Access
CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study
Value in Health·2025
Supplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for &lt;i&gt;IDH1&lt;/i&gt;-Mutated Acute Myeloid Leukemia
2025Open Access
Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for &lt;i&gt;IDH1&lt;/i&gt;-Mutated Acute Myeloid Leukemia
2025Open Access
Supplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for &lt;i&gt;IDH1&lt;/i&gt;-Mutated Acute Myeloid Leukemia
2025Open Access
Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for &lt;i&gt;IDH1&lt;/i&gt;-Mutated Acute Myeloid Leukemia
2025Open Access
&lt;i&gt;IDH2&lt;/i&gt; mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
Haematologica·2025· 1 citedOpen Access
A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium
Blood·2025Open Access
page 1 of 23Next →

Frequent Co-authors

John C. Byrd(18), Richard M. Stone(17), William Blum(16), Amir T. Fathi(12), James S. Blachly(12), James M. Foran(11), Eytan M. Stein(10), Daniel A. Pollyea(10), Martin S. Tallman(10), Shelley Orwick(10), Hagop M. Kantarjian(9), Courtney D. DiNardo(8), Jessica K. Altman(8), Gabriel N. Mannis(8), Geoffrey L. Uy(8), Wendy Stock(8), Ann‐Kathrin Eisfeld(8), Jessica Kohlschmidt(8), Krzysztof Mrózek(8), Sung Choe(7)